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ABSTRACT 
Presence or absence of anti-HIV p17 was evaluated by western blot analysis for its usefulness 
as a marker to estimate the onset of AIDS or ARC. Replication of HIV and decline of anti-
HIV immunity have been considered to be causative of the onset of the diseases. Although 
the isolation of HIV from peripheral blood mononuclear cells is one of the reliable markers but， 
this can be affected by the use of antiviral drugs， such as Zidovudine. 
Determination of anti-P17 is also a useful HIV marker to indicate the development of symp-
toms. Conversion of anti-P17 positive to negative may occur with the increase in p17 antigen 
concentration. Two types of comparison have heen made : (1) anti-p17 negativity and clinical 
status， (2) anti-p17 negativity and successful HIV isolation. Anti-P17 negativity correlated 
with deterioration of clinical status (CDC 2 or 3 to 4) (pく0.01)and successful HIV isolation 
(pく0.05). After the administration of drugs the result of antibodY test did not fluctuate 
between negative and positive. Therefore， anti働p17has an advantage in judging the "pre-
symptomatic stage" rather than HIV isolation. One case encountered symptomatic stage 
without negative conversion of anti-P17 and successful HIV isolation. This may imply that 
decline in some of other anti-HIV immune status may also play an important role in developing 
sy立1ptO紅lS.
発症後4年以内にほぼ全員が死亡するという致死率






(Accepted on August 19， 1989) 
lと発症病理の理解が不可欠であるがいまだにその詳細
は不明である.CD4陽性細胞の死が発症の直接的な









































































病 型 症抗例p1数7(抗割/合体検)討陰性症判例定数 検分討離(割症鶴合性例)数 /
CDC 2or3若手 6/19 (325ぢ)っ 9/19 (4796) 
* CDC 4 群 14/16 (885的J 10/16 (6396) 


















経過〈月〉 O 5 10 15 20 
CDC病型群 444 4 
ジドブジン * * * 
HIV分離 十一一
抗p17抗体 十十十 十
* :ジドブジン投与時期. 一:陰性. 十:陽性.
症例 2 
経過(月〉 O 5 











経過(月〉 O 5 
























10 15 20 














経過(月) O 5 10 15 20 
CDC病型群 3 3 3 3 3 333 3 3 3 333 4 




経過(月〉 O 5 




経 i品(月〉 O 5 




経過(月〉 O 5 




経過(月〉 O 5 








10 15 20 
4 4 4 
十 十 十
10 15 20 
2 2 4 4 
10 15 20 
4 
+ 












経過(月) O 1 2 3 4 5 
CDC病型群 2 2 2 222 
HIV分離 + 十 十 十十+
抗p17抗体 十 十 一一+
陰性. 十:I弱性.
症例 11 
経過(月〉 O 1 2 3 4 5 
CDC病型群 2 2 2 222 
HIV分離 +十十
抗p17抗体 十 + 十 - +十
症例 12 
経過(月) O 1 2 3 4 5 
CDC病型群 2 2 2 222 
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